Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency

Romain Lévy, Satoshi Okada, Vivien Béziat, Kunihiko Moriya, CaiNi Liu, Louis Yi Ann Chai, Mélanie Migaud, Fabian Hauck, Amein Al Alig, Cyril Cyrus, Chittibabu Vatte, Turkan Patiroglu, Emek Unal, Marie Ferney, Nobuyuki Hyakuna, Serdar Nepesov, Matias Oleastro, Aydan Ikindicogullari, Figen Dogu, Takaki Asano, Osamu Ohara, Ling Yun, Erika Della Mina, Didier Bronnimann, Yuval Itan, Florian Gothe, Jacinta Bustamante, Stéphanie Boissuin-Dupuis, Natalia Tahui, Caner Aytken, Aicha Salhi, Saleh Al Muhens, Masao Kobayashi, Julie Toubiana, Laurent Abel, Xiaoxia Li, Yildiz Camcioglu, Fatih Celmei, Christoph Klein, Suzan A. AlKhater, Jean-Laurent Casanova, Anne Puel.

Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, 75015 Paris, France; Imagine Institute, Paris Descartes University, 75015 Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY 10065; Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, 734-8551, Japan; Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195; Department of Pediatrics, Dr. von Hauner Children’s Hospital, Ludwig-Maximilians-University, 80337 Munich, Germany; Institute for Research and Medical Consultation, University of Dammam, Dammam 31441, Saudi Arabia; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Faculty of Medicine, Erciyes University, 38030 Kayseri, Turkey; Department of Dermatology, Necker Hospital for Sick Children, 75015 Paris, France; Center of Bone Marrow Transplantation, Faculty of Medicine, University of the Ryukyus, Okinawa 903-0623, Japan; Division of Infectious Diseases, Clinical Immunology and Allergy, Department of Pediatrics, Cerrahpasa Medical Faculty, Istanbul University, 34452 Istanbul, Turkey; Department of Immunology and Rheumatology, Juan P. Garrahan National Pediatric Hospital, C1245AAM Buenos Aires, Argentina; Department of Pediatric Immunology and Allergy, Ankara University School of Medicine, 06100 Ankara, Turkey; Department of Technology Development, Kazusa DNA Research Institute, Chiba 292-0818, Japan; Center for the Study of Primary Immunodeficiencies, Necker Hospital for Sick Children, 75015 Paris, France; Department of Immunology, Hospital Del Niño Jesús, 4000 San Miguel de Tucumán, Tucumán, Argentina; Department of Pediatric Immunology, Dr. Sami Ulus Maternity and Children’s Health and Diseases Training and Research Hospital, 06080 Ankara, Turkey; Department of Dermatology, Algiers Faculty of Medicine, University of Algiers, Algiers 16030, Algeria; Prince Naif Center for Immunology Research, King Saud University, Riyadh 12372, Saudi Arabia; Department of General Pediatrics and Pediatric Infectious Diseases, Assistance Publique-Hôpitaux de Paris, Necker Hospital for Sick Children, 75015 Paris, France; Division of Infectious Diseases, Clinical Immunology and Allergy, Department of Pediatrics, Cerrahpasa Medical Faculty, Istanbul University, 34452 Istanbul, Turkey; Department of Pediatric Immunology and Allergy, Antalya Education and Research Hospital, 07070 Antalya, Turkey; Department of Pediatrics, College of Medicine, King Fahad Hospital of the University, University of Dammam, Al-Khobar 31952, Saudi Arabia; Pediatric Hematology-Immunology Unit, Necker Hospital for Sick Children, 75015 Paris, France; and Howard Hughes Medical Institute, New York, NY 10065

Contributed by Jean-Laurent Casanova, November 10, 2016 (sent for review August 29, 2016; reviewed by Kai Kisand and Mikko Seppanen)

Chronic mucocutaneous candidiasis (CMC) is defined as recurrent or persistent infection of the skin, nails, and/or mucosae with commensal Candida species. The first genetic etiology of isolated CMC—autosomal recessive (AR) IL-17 receptor A (IL-17RA) deficiency—was reported in 2011, in a single patient. We report here 21 patients with complete AR IL-17RA deficiency, including this first patient. Each patient is homozygous for 1 of 12 different IL-17RA alleles, of which create a premature stop codon upstream from the transmembrane domain and have been predicted and/or shown to prevent expression of the receptor on the surface of circulating leukocytes and dermal fibroblasts. Three other mutant alleles create a premature stop codon downstream from the transmembrane domain, one of which encodes a surface-expressed receptor. Finally, the only known missense allele (p.D387N) also encodes a surface-expressed receptor. All of the alleles tested abolish cellular responses to IL-17A and -17F homodimers and heterodimers in fibroblasts and to IL-17/E/IL-25 in leukocytes. The patients are currently aged from 2 to 35 y and originate from 12 unrelated kindreds. All had their first CMC episode by 6 mo of age. Fourteen patients presented various forms of staphylococcal skin disease. Eight were also prone to various bacterial infections of the respiratory tract. Human IL-17RA is, thus, essential for mucocutaneous immunity to Candida and Staphylococcus, but otherwise largely redundant. A diagnosis of AR IL-17RA deficiency should be considered in children or adults with CMC, cutaneous staphylococcal disease, or both, even if IL-17RA is detected on the cell surface.

Significance

Chronic mucocutaneous candidiasis (CMC) is defined as persistent or recurrent infections of the skin and/or mucosae by commensal fungi of the Candida genus. It is often seen in patients with T-cell deficiencies, whether inherited or acquired, who typically suffer from multiple infectious diseases. Rare patients are otherwise healthy and display isolated CMC, which often segregates as a Mendelian trait. In 2011, we described the first genetic cause of isolated CMC, with autosomal recessive (AR), complete IL-17 receptor A (IL-17RA) deficiency, in a single patient. We report here 21 patients from 12 unrelated kindreds, homozygous for 12 different mutant alleles that underlie AR IL-17RA deficiency. All patients have isolated CMC and their cells do not respond to IL-17A, -17F, and -17/E/IL-25.


Reviewers: K.K., University of Tartu; and M.S., Helsinki University Hospital.

The authors declare no conflict of interest.


Reviewers: K.K., University of Tartu; and M.S., Helsinki University Hospital.

The authors declare no conflict of interest.

5To whom correspondence may be addressed. Email: casanova@rockefeller.edu or anne.puel@inserm.fr.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1618300114/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1618300114

PNAS | Published online December 7, 2016 | E8277–E8285
of CMC are less common and are often associated with other infectious and noninfectious complications, particularly in patients with profound T-cell deficits (1). Patients with autosomal dominant (AD) hyper-IgE syndrome (HIES), caused by heterozygous dominant negative mutations of STAT3, display fewer infections, and patients with autosomal recessive (AR) autoimmune polyendocrine syndrome type 1 (APS-1) are not prone to other infections (2, 3). Finally, rare patients with inherited but idiopathic forms of CMC, referred to as CMC disease (CMCD), have been described since the late 1960s (4–8). These patients may display isolated CMC, but they often also display cutaneous staphylococcal disease (nonetheless referred to as CMCD) or other infectious and/or autoimmune clinical manifestations (symdromic CMCD).

The genetic causes of CMCD described to date include AR IL-17RA deficiency in a single patient (9), AD IL-17F deficiency in a multiplex kindred (9), AR IL-17RC deficiency in three kindreds (10), and AR ACT1 deficiency in a multiplex kindred (ACT1 is a cytosolic adapter of IL-17 receptors) (11). IL-17RA and -17RC belong to the IL-17 receptor family, which also includes the IL-17RB, -17RD, and -17RE chains. These receptors form various heterodimers, through which different IL-17 cytokines signal in an ACT1-dependent manner (12). Finally, AD signal transducer and activator of transcription 1 (STAT1) gain of function (GOF) was reported in ~350 patients with syndromic CMCD (13–51) and found in approximately half of such patients in our study cohort. In patients with STAT1 GOF mutations, CMC results, at least partly, from impairment of the development and/or survival of IL-17A/F–producing T cells, the underlying mechanisms of which remain unknown (28, 52). Patients with these mutations, who had long been known to be prone to thyroid autoimmune, were recently found to display other infectious and autoimmune phenotypes (16, 17, 23, 37, 51). Another genetic etiology of syndromic CMCD has recently been described, with AR retinoic acid-related orphan receptors γ (ROR-γ/γ T) deficiency in three kindreds with CMC and severe mycobacterial disease (53).

AD HIES and AR APS-1 can, thus, also be seen as syndromic forms of CMCD. Alternatively, STAT1 GOF and ROR-γ/γ T deficiency can be seen as distinct entities, separate from CMCD. In either case, impaired IL-17A/F– or IL-17RA/RC–dependent immunity is the core mechanism accounting for CMC in patients with these mutations, which are inherited in a recessive (and the corresponding premature stop codons), were located upstream from the segment encoding the transmembrane domain of IL-17RA. By contrast, the p.Y384X nonsense, p.D387N missense, and p.N440Rfs*50 frameshift variants affected the intracellular SEFIR (SEF/IL-17R) domain of IL-17RA, which is required for ACT1 recruitment, whereas the p.Y591Sfs*29 frameshift variant was located in the SEFEX domain (SEFIR extension domain) (61, 62). The healthy parents and siblings tested were all heterozygous for the mutant alleles or homozygous for the wild-type allele, consistent with an AR mode of inheritance with full clinical penetrance. None of the 12 mutant alleles were found in any of the various public databases (Exome Aggregation Consortium, Human Gene Mutation Database, Ensembl, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project, and 1000 Genomes Project), our in-house WES database (>3,000 exomes), or the Greater Middle Eastern Variome (63), further suggesting that the mutant alleles were causal for CMCD. The p.D387N missense mutation affected a residue conserved throughout evolution. As expected, combined annotation dependent depletion (CADD) scores predicted all mutations to be deleterious and were well above the mutation significance cutoff score for IL17RA (Table 1) (64, 65). These data strongly suggested that the 21 patients suffered from AR IL-17RA deficiency.

Expression and Function of the Mutant IL17RA Alleles. IL-17RA expression was tested on the surface of primary or SV40-transformed fibroblasts and/or lymphocyte subsets and monocytes from

Results

Clinical Reports. We investigated 21 patients with early onset, unexplained CMC (Fig. 1A). The patients originated from Morocco (kindred A), Turkey (kindred B, C, D, E, K, and L), Japan (kindred F), Saudi Arabia (kindreds G and J), Algeria (kindred H), and Argentina (kindred I). The clinical features of patient 1 (P1) (kindred A), born to first cousins from Morocco, have already been reported (9). The 12 families were unrelated, and 11 were known to be consanguineous. All patients displayed CMC before the age of 6 mo, and 14 patients had also suffered from recurrent staphylococcal skin infections by the same age. CMC affected the skin (intertrigo), the scalp, mucosal sites (oral thrush; anogenital candidiasis), or nails (Table 1). These episodes were effectively managed or prevented with a combination of oral (fluconazole) and topical (nystatin) antifungal treatments. Staphylococcal skin infections were reported in 14 patients suffering from abscesses, folliculitis, furunculosis, and crusted pustules on the face and scalp, sometimes spreading to the shoulders and arms. In addition to these skin infections, eight children also had other recurrent infections, including otitis, sinusitis, bronchitis, and lobar pneumonia. Infections typically responded to antibiotics, but subsequently recurred. P2 and P4 were also treated for suspected pulmonary tuberculosis and tuberculous meningitis, respectively, without microbiological confirmation. None of the other clinical manifestations previously reported in patients with GOF STAT1 mutations, such as autoimmune endocrinopathy, aneurysms, or mucosal carcinomas, were detected (16, 17, 23, 37, 51). Detailed phenotyping of lymphocyte subsets was performed for patients from kindreds D, E, and H and revealed no abnormality (Fig. S1).

Mutations in IL17RA. WES was performed for all patients and led to the detection of biallelic IL17RA mutations, which were confirmed by Sanger sequencing (Fig. 1A). No nonsynonymous coding sequence mutations were identified in the other five genes implicated in CMCD (IL17F, IL17RC, ACT1, STAT1, and RORC) or in any of the genes known to underlie related primary immunodeficiencies, including APS-1 and AD HIES. As shown in Fig. 1B, the only essential splice variant, three nonsense and four frameshift variants (and the corresponding premature stop codons), were located upstream from the segment encoding the transmembrane domain of IL-17RA. By contrast, the p.Y384X nonsense, p.D387N missense, and p.N440Rfs*50 frameshift variants affected the intracellular SEFIR (SEF/IL-17R) domain of IL-17RA, which is required for ACT1 recruitment, whereas the p.Y591Sfs*29 frameshift variant was located in the SEFEX domain (SEFIR extension domain) (61, 62). The healthy parents and siblings tested were all heterozygous for the mutant alleles or homozygous for the wild-type allele, consistent with an AR mode of inheritance with full clinical penetrance. None of the 12 mutant alleles were found in any of the various public databases (Exome Aggregation Consortium, Human Gene Mutation Database, Ensembl, National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project, and 1000 Genomes Project), our in-house WES database (>3,000 exomes), or the Greater Middle Eastern Variome (63), further suggesting that the mutant alleles were causal for CMCD. The p.D387N missense mutation affected a residue conserved throughout evolution. As expected, combined annotation dependent depletion (CADD) scores predicted all mutations to be deleterious and were well above the mutation significance cutoff score for IL17RA (Table 1) (64, 65). These data strongly suggested that the 21 patients suffered from AR IL-17RA deficiency.
seven patients homozygous for six mutant IL17RA alleles (Fig. 2). IL-17RA expression was abolished on fibroblasts (P1, P2, and P4) (Fig. 2A) and peripheral blood mononuclear cells (PBMCs) [P1 (9), P3, and P13] (Fig. 2C), except for those from P5 (p.D387N), for whom IL-17RA was barely and normally detectable in SV40 fibroblasts and monocytes, respectively (Fig. 2A and C). In addition,
<table>
<thead>
<tr>
<th>Patient (kindred)</th>
<th>Age at diagnosis</th>
<th>Genotype [CADD score]</th>
<th>Sex</th>
<th>Consanguinity</th>
<th>Origin</th>
<th>Mucocutaneous features</th>
<th>Other clinical features</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1 (9) (A)</td>
<td>1 mo</td>
<td>c.850C &gt; T p.Q284X [40]</td>
<td>M</td>
<td>Yes</td>
<td>Morocco (living in France)</td>
<td>Skin, nails and oral mucosal candidiasis Skin pustules, folliculitis</td>
<td>No</td>
</tr>
<tr>
<td>P2 (B)</td>
<td>18 mo</td>
<td>c.256C &gt; T p.Q86X [30]</td>
<td>F</td>
<td>Yes</td>
<td>Turkey</td>
<td>Genital and oral mucosal candidiasis</td>
<td>Suspected pulmonary tuberculosis</td>
</tr>
<tr>
<td>P3 (C)</td>
<td>1 mo</td>
<td>c.1302_1318dup p.N440Rfs*50 [22]</td>
<td>F</td>
<td>Yes</td>
<td>Turkey (living in France)</td>
<td>Scalp, genital and oral mucosal candidiasis Skin pustules, folliculitis</td>
<td>Eczema</td>
</tr>
<tr>
<td>P4 (C)</td>
<td>2 mo</td>
<td>c.1302_1318dup p.N440Rfs*50 [22]</td>
<td>M</td>
<td>Yes</td>
<td>Turkey (living in France)</td>
<td>Genital and oral mucosal candidiasis Skin pustules, folliculitis</td>
<td>Eczema, suspected tuberculous meningitis, lobar pneumonia</td>
</tr>
<tr>
<td>P5 (D)</td>
<td>9 y</td>
<td>c.1159G &gt; A p.D387N [33]</td>
<td>M</td>
<td>Yes</td>
<td>Turkey</td>
<td>Scalp and oral mucosal candidiasis Skin pustules, folliculitis, furunculosis, seborrheic dermatitis</td>
<td>Sinusitis, lobar pneumonia</td>
</tr>
<tr>
<td>P6 (D)</td>
<td>4 y</td>
<td>c.1159G &gt; A p.D387N [33]</td>
<td>F</td>
<td>Yes</td>
<td>Turkey</td>
<td>Scalp, genital and oral mucosal candidiasis Skin pustules, furunculosis, seborrheic dermatitis</td>
<td>Conjunctivitis</td>
</tr>
<tr>
<td>P7 (E)</td>
<td>1.5 y</td>
<td>c.166_169dup p.C57Yfs*5 [34]</td>
<td>F</td>
<td>Yes</td>
<td>Turkey</td>
<td>Skin, scalp, nails, genital and oral mucosal candidiasis Skin pustules, folliculitis, furunculosis</td>
<td>Sinusitis</td>
</tr>
<tr>
<td>P8 (E)</td>
<td>1 y</td>
<td>c.166_169dup p.C57Yfs*5 [34]</td>
<td>M</td>
<td>Yes</td>
<td>Turkey</td>
<td>Skin, scalp, nails and oral mucosal candidiasis Skin pustules, folliculitis, furunculosis</td>
<td>Sinusitis, conjunctivitis</td>
</tr>
<tr>
<td>P10 (F)</td>
<td>6 y</td>
<td>c.199C &gt; T p.R66X [14]</td>
<td>M</td>
<td>No</td>
<td>Japan</td>
<td>Skin, scalp and oral mucosal candidiasis Folliculitis</td>
<td>Eczema, bronchitis, lobar pneumonia</td>
</tr>
<tr>
<td>P11 (G)</td>
<td>25 y</td>
<td>c.112_119del p.H38Af5*15 [34]</td>
<td>M</td>
<td>Yes</td>
<td>Saudi Arabia</td>
<td>Oral mucosal candidiasis</td>
<td>No</td>
</tr>
<tr>
<td>P12 (G)</td>
<td>15 y</td>
<td>c.112_119del p.H38Af5*15 [34]</td>
<td>F</td>
<td>Yes</td>
<td>Saudi Arabia</td>
<td>Oral mucosal candidiasis</td>
<td>No</td>
</tr>
<tr>
<td>P13 (H)</td>
<td>1 mo</td>
<td>c.163_16G &gt; A [25]</td>
<td>F</td>
<td>Yes</td>
<td>Algeria</td>
<td>Skin and genital mucosal candidiasis</td>
<td>No</td>
</tr>
<tr>
<td>P14 (I)</td>
<td>1 y</td>
<td>c.1152C &gt; A p.Y384X [38]</td>
<td>M</td>
<td>Yes</td>
<td>Argentina</td>
<td>Skin and oral mucosal candidiasis Skin pustules, folliculitis, furunculosis, abscess</td>
<td>Sinusitis, otitis, lobar pneumonia</td>
</tr>
<tr>
<td>P15 (J)</td>
<td>4 y</td>
<td>c.268del p.L90Cfs*30 [23]</td>
<td>F</td>
<td>Yes</td>
<td>Saudi Arabia</td>
<td>Skin, genital and oral mucosal candidiasis</td>
<td>No</td>
</tr>
<tr>
<td>P16 (J)</td>
<td>2 y</td>
<td>c.268del p.L90Cfs*30 [23]</td>
<td>M</td>
<td>Yes</td>
<td>Saudi Arabia</td>
<td>Skin, scalp, nails, genital and oral mucosal candidiasis</td>
<td>No</td>
</tr>
<tr>
<td>P17 (J)</td>
<td>15 y</td>
<td>c.268del p.L90Cfs*30 [23]</td>
<td>M</td>
<td>Yes</td>
<td>Saudi Arabia</td>
<td>Skin, scalp and oral mucosal candidiasis Folliculitis, furunculosis</td>
<td>No</td>
</tr>
<tr>
<td>P18 (J)</td>
<td>10 y</td>
<td>c.268del p.L90Cfs*30 [23]</td>
<td>M</td>
<td>Yes</td>
<td>Saudi Arabia</td>
<td>Skin, scalp and oral mucosal candidiasis Folliculitis, furunculosis</td>
<td>No</td>
</tr>
<tr>
<td>P19 (K)</td>
<td>22 y</td>
<td>c.1770_1771dup p. Y591fs*29 [26.7]</td>
<td>M</td>
<td>Yes</td>
<td>Turkey</td>
<td>Skin, scalp, nails and oral mucosal candidiasis Skin pustules</td>
<td>Otitis</td>
</tr>
<tr>
<td>P20 (L)</td>
<td>13 y</td>
<td>c.769_773del p. P257Rfs*16 [28]</td>
<td>F</td>
<td>Yes</td>
<td>Turkey</td>
<td>Oral mucosal candidiasis Skin abscess</td>
<td>No</td>
</tr>
<tr>
<td>P21 (L)</td>
<td>11 y</td>
<td>c.769_773del p. P257Rfs*16 [28]</td>
<td>F</td>
<td>Yes</td>
<td>Turkey</td>
<td>Oral mucosal candidiasis</td>
<td>No</td>
</tr>
</tbody>
</table>
the p.Y591Sfs*29 allele (P19) was normally expressed in primary fibroblasts (Fig. 2B). The intracellular D387 residue is highly conserved and located in the SEFIR domain, which engages in homotypic dimerization with the SEFIR domain of ACT1 for IL-17RA signaling. We therefore tested HEK293T cells overproducing the p.D387N protein for interactions of this protein with ACT1, by immunoprecipitation and Western blotting; we found that the interaction of these two proteins was severely impaired in these cells (Fig. S2). We then investigated the function of p.D387N, together with several loss-of-expression alleles, by stimulating patient fibroblasts with high doses of recombinant IL-17A, -17F, and -17A/F heterodimers, with or without the addition of TNF-α. We detected no induction of IL-6 and GRO-α in any condition, whereas the induction of these two proteins was observed in control cells (Fig. 3 and Fig. S3A and B). We measured the induction of mRNA for the antimicrobial peptide BD2 (β-defensin 2) in patient fibroblasts stimulated with IL-17A plus TNF-α. We found no up-regulation in cells homozygous for p.D387N or p.Q284X, whereas such induction was observed in control cells (Fig. S3C). We then tested the response to IL-17E/IL-25 in the presence of IL-2 in PBMCs from P5 and P6 (p.D387N). No induction of IL-5 was observed, in contrast to the results obtained for control PBMCs (Fig. S4). Finally, the transfection of fibroblasts from P1 and P5 with a WT IL-17RA-encoding vector partially restored both surface IL-17RA expression (Fig. S5) and the response to IL-17A plus TNF-α (Fig. 4 and Fig. S6). Overall, these data indicate that p.D387N is loss of function. All patients displayed complete AR IL-17RA deficiency, with a lack of cellular responses to IL-17A, -17F, and -17A/F in fibroblasts, as well as to IL-17E/IL-25 in PBMCs.

**Abnormally High Proportions of IL-17–Producing T Cells and a Normal Response of Whole Blood to Candida and Staphylococcus.** Given the critical role of IL-17A/F–producing T cells in immunity to *Candida* at barrier sites, we carried out an ex vivo assessment of the proportions of IL-17A/F–producing memory CD4+ T cells in patients. The patients tested (kindreds C, D, E, and H) had significantly higher proportions of IL-17A– and IL-17F–producing memory CD4+ T cells ex vivo than controls and healthy relatives, after stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, but similar or slightly higher proportions of IL-22–producing memory CD4+ T cells (Fig. 5A). By the mean values for IL-17A and -22 secretion levels in whole-blood assays were slightly higher than those for controls and healthy relatives, although this difference was not significant. This difference probably resulted from the smaller numbers of memory CD4+ T cells in patients than in adult controls and healthy relatives (Fig. 5B and Fig. S1). We also carried out whole-blood assays to assess the response to different stimuli, including zymosan, curdlan, lipopolysaccharide (LPS), vesicular stomatitis virus (VSV), Bacille de Calmette et Guérin (bacillus Calmette–Guérin), *Staphylococcus aureus*, and yeasts (*C. albicans*, *Saccharomyces cerevisiae*, and *Exophiala dermatitidis*), by...
measuring the secretion of IL-6, -17A, and IFN-γ. Similar responses were observed for controls, the patients, and their healthy heterozygous relatives (Fig. S7). The results of these two sets of experiments suggest that the reported infectious phenotype in patients cannot be assigned to a defect in the mounting of a potent IL-17 inflammatory response or to S. aureus and C. albicans. Instead, they suggest that the susceptibility to S. aureus and C. albicans reported in IL-17RA-deficient patients results from a complete lack of response to at least IL-17A, -17F, -17A/F, and -17E/IL-25.

Discussion

We report complete AR IL-17RA deficiency in 21 patients from 12 unrelated kindreds and 6 ethnic groups (9). All 12 alleles, including the 2 alleles (p.D387N and p.Y591Sfs*29) encoding surface-expressed receptors, are loss-of-function in terms of responses to IL-17A, -17F, and -17A/F in fibroblasts. In addition, p.D387N is also loss-of-function for the response to IL-17E/IL-25 in PBMCs. Interestingly, the missense allele encodes a surface receptor in monocytes only. The clinical and cellular phenotypes of the two patients with this allele did not differ from those of patients with loss-of-expression alleles. This finding suggests that the p.D387N allele encodes a receptor that is present but not functional on monocytes, due to impairment of the SEFIR-mediated interaction with the adaptor ACT1. An alternative, but less likely, hypothesis is that IL-17RA-dependent signaling in monocytes may be redundant for mucocutaneous immunity to Candida.

The cell-surface expression of dysfunctional receptors is the second genetic form of AR IL-17RA deficiency to be described. The detection of surface IL-17RA should not, therefore, exclude a diagnosis of IL-17RA deficiency, as previously shown for other cytokine receptors, such as IFN-γR1 (66–69), IFN-γR2 (70, 71), IL-12Rβ1 (72, 73), and IL-10RA (74, 75). IL-17RA deficiency has recently been reported in two siblings from Sri Lanka (60). These siblings are homozygous for a large chromosomal deletion, also encompassing CECR1 (encoding ADA2) and XKIR3 (encoding X Kell blood group-related 3). These two patients displayed...
CMC and staphylococcal skin infections, together with a chronic inflammatory disease possibly related to ADA2 deficiency. Collectively, these clinical observations suggest that AR IL-17RA deficiency is the second most common known genetic etiology of CMCMD, after GOF STAT1, and the most common known etiology of isolated, as opposed to syndromic, CMCMD (51).

All of the IL-17RA alleles tested were null, because the responses to IL-17A/IL-17F homodimers and heterodimers in the patients’ fibroblasts (cells tested displaying the best induction of IL-6 and GRO-α in controls)—and, by inference, probably in PBMCs (9)—and responses to IL-17E/IL-25 in their PBMCs were abolished. We predict that none of the cell types normally expressing IL-17RA in healthy individuals (whether hematopoietic or nonhematopoietic) respond to IL-17RA–deficient cytokines in patients. Nevertheless, the susceptibility to infection of IL-17RA–deficient patients appeared to be restricted to certain mucocutaneous barrier sites. In addition to CMC and cutaneous staphylococcal infections, several patients presented bacterial infections of the respiratory tract, which may not be coincidental (76). In a mouse model of *Klebsiella pneumoniae* infection, IL-17RA signaling has been shown to be critical for the optimal production of chemokines and granulocyte colony-stimulating factor in the lungs and for neutrophil recruitment and survival (77). The skin and mucosal phenotype of the patients may be accounted for, at least in part, by human keratinocytes and bronchial epithelial cells having a much greater dependence than other cell types on the synergistic effect of IL-17 cytokines (IL-17A and -17F in particular) and inflammatory cytokines (such as TNF-α) for the production of chemokines and antimicrobial peptides (78). It remains unclear how IL-17A, -17F, -17A/F, and -17E/IL-25 deficiency in patients with IL-17RA deficiency confers a more severe phenotype in patients with ACT1 or IL-17RA deficiency. Patients with ACT1 or IL-17RA deficiency are also susceptible to staphylococcal skin infections and bacterial respiratory infections, which tend to run a more chronic course. It is too early to draw firm conclusions, given the small number of patients identified. However, each of these genetic defects may have a different impact on IL-17 immunity. For example, in addition to acting in concert with IL-17RC for responses to IL-17A/F, IL-17RA acts with IL-17RB in mice (81) and with IL-17RE in mice and humans (82, 83) in responses to IL-17E/IL-25 and -17C, respectively. The function of IL-17RD is poorly defined and its ligand is unknown, but studies in mice have shown that ACT1 is essential for the signal transduction mediated by the individual IL-17RA (84, 85), IL-17RB (86), IL-17RC (87), and IL-17RE (88) subunits. Unlike those of IL-17RC–deficient patients, PBMCs from ACT1-deficient and IL-17RA–deficient patients do not respond to IL-17E/IL-25 (10, 11). The role of human IL-17E/IL-25 is unknown, in the absence of known patients bearing specific mutations, but its mouse counterpart is known to promote "Th2"–mediated responses (89, 90) and to be involved in immunity to parasitic infections (91–93). We were unable to detect cellular responses to IL-17B, -17D, and even -17C (83) in control fibroblasts, keratinocytes, or leukocytes. This finding precluded the testing of such responses in IL-17RA–deficient or other patients with CMC. Human IL-17C may play a redundant role in protective mucocutaneous immunity to *Candida*, because IL-17C– and IL-17RE–deficient mice clear *Candida* infections normally (94). The role of each human IL-17 cytokine in vivo will be determined from the description of patients bearing mutations, as reported for IL-17F (9). Overall, our data demonstrate that human signaling via IL-17RA (in response to at least IL-17A, -17A/F, -17F, and -17E/IL-25) is essential for mucocutaneous immunity to *C. albicans* and *Staphylococcus*. They also suggest that IL-17RA–dependent signaling is important for protective immunity to various bacteria in the respiratory tract.

**Materials and Methods**

**Massively Parallel Sequencing.** Genomic DNA extracted from the peripheral blood cells of each patient was sheared with a Covaris S2 Ultrasonicator. An adaptor-ligated library was prepared with the Paired-End Sample Prep kit V1 (Illumina). Exome capture was performed with the SureSelect Human All Exon kit (Agilent Technologies). Single-end sequencing was performed on an Illumina Genome Analyzer Iix (Illumina), generating 72-base reads.

**Molecular Genetics.** Genomic DNA was isolated from whole blood by phenol/chloroform extraction method. IL17RA gDNA was amplified with specific primers (PCR amplification conditions and primer sequences are available in Table S1). PCR products were analyzed by electrophoresis in 1% agarose gels, sequenced with the Big Dye Terminator cycle sequencing kit (Applied Biosystems), and analyzed on an ABI Prism 3700 (Applied Biosystems).

**Cell Activation.** For the ex vivo evaluation of IL-17A– and IL-22–producing T cells by ELISA, we used 250 μL of whole blood diluted in RPMI (500 μL final volume) to seed 48-well plates. We added 40 ng/mL PMA and 10−5 M ionomycin and incubated the plates for 24 h. The supernatants were then collected for ELISA (R&D Systems). For the evaluation of the response to IL-17E/IL-25, fresh PBMCs were cultured in the presence of 100 ng/mL thymic stromal lymphopoietin (R&D Systems; 1398-TS-0100F) in x-VIVO 15 (Lonza) plus 5% human AB serum (Lonza) for 24 h. PBMCs were collected, washed, and resuspended at a density of 4 × 10^6 cells per well in 48-well plates, in a final volume of 0.5 mL per well, in the presence of 10 ng/mL recombinant human IL-2 (R&D Systems) and 10 ng/mL recombinant human IL-17E (R&D Systems). After 3 d, IL-5 secretion was assessed by ELISA (DY205; R&D Systems). SV40-transformed fibroblasts were plated in 48-well plates at a density of 100,000 cells per well in 0.5 mL of DMEM/10% (vol/vol) FBS. They were incubated for 24 h and then left unstimulated or stimulated for 24 h with recombinant human IL-17A, -17F, and -17A/F (100 ng/mL), with or without TNF-α (20 ng/mL) purchased from R&D Systems. The supernatants were collected for ELISA for IL-6 (Sanquin) and GRO-α (R&D Systems), carried, and run on in accordance with the kit manufacturer’s instructions.

**Flow Cytometry.** For the ex vivo evaluation of IL-17A–, IL-17F–, IL-22–, and IFN-γ–producing T cells by flow cytometry, PBMCs were dispensed into 48-well plates at a density of 3 × 10^6 cells per mL in RPMI/10% (vol/vol) FBS for 12 h with 40 ng/mL PMA plus 10−5 M ionomycin, in the presence of a secretion inhibitor (1 μM GolgiPlug; BD Biosciences). The cells were washed and surface-labeled with PE-Cy7 mouse anti-human CD3 (SK7; BD Biosciences), CD4-APC-Vio770, human (M-T321; Miltenyi Biotec), Brilliant Violet 421 anti-human CD197 (CCR7) (G043H7; BD Biosciences), and LIVE/DEAD Fixable Aqua Dead Cell, Alexa Fluor 488 anti-human CD4 (E8283;ebiosciences), and analyzed on an ABI Prism 3700 (Applied Biosystems). SV40-transformed fibroblasts were plated in 48-well plates at a density of 100,000 cells per well in 0.5 mL of DMEM/10% (vol/vol) FBS. They were incubated for 24 h and then left unstimulated or stimulated for 24 h with recombinant human IL-17A, -17F, and -17A/F (100 ng/mL), with or without TNF-α (20 ng/mL) purchased from R&D Systems. The supernatants were collected for ELISA for IL-6 (Sanquin) and GRO-α (R&D Systems), carried out in accordance with the kit manufacturer’s instructions.
Cell Complementation. IL-17RA-deficient SV40-transformed fibroblasts were transfected with either empty pORF9-mcs vectors or with the pORF9-ΔL78 vector encoding the wild-type human IL-17A (Cayla-In vivogen), with the Lipofectamine LTX transfection kit (Invitrogen), according to the manufacturer’s instructions. At 24 h later, cells were stimulated with IL-17A (100 ng/mL), with or without TNF-α (20 ng/mL), for a further 24 h. The supernatants were collected for the assessment of IL-6 and GRO-α levels by ELISA, and the cells were collected for the evaluation of IL-17A expression by FACs analysis.

Full-Length RT-PCR for DEFB4A and Taqman Probe Detection. Total RNA was extracted with the RNeasy minikit (Qiagen) and reverse-transcribed to cDNA, with the High Capacity cDNA Reverse Transcription Kit (4368813; Invitrogen). Taqman probes for DEFB4A (Hs00823638_m1; Invitrogen) were used to detect mRNA synthesis, with normalization on the basis of GUS expression (Human GUSB Endogenous Control VIC/MGB Probe; 4326320E; Primer Limited; Invitrogen).

Healthy Controls. The healthy controls were volunteer blood donors of European and Turkish origin.

Study Approval. The experiments described here were conducted in accordance with local, national, and international regulations and were approved by the French Ethics committee (CPP Ile-de-France 2, ID-RCB: 2010-A00636-33), French National Agency for Medicines and Health Products Safety (B100712-40), and the French Ministry of Research (IE-2010-547). Informed consent was obtained from all patients or their families, in the case of minors, in accordance with World Medical Association rules, the Helsinki Declaration, and European Union directives.

ACKNOWLEDGMENTS. We thank the members of the laboratory for helpful discussions; Yelena Nemiroskaya, Eric Anderson, Martine Courat, and Lahouari Aamar for expert secretarial assistance; and Maya Chrabieh, Lazaro Lorenzo, and Tiffany Nivare for technical assistance. This work was supported by French National Research Agency (ANR) Grants ANR GENCMC11-11BSV5-0011 (to A.P.), ANR EURO-CMC-14-RARE-0005-02), and “Investissement d’avenir” Program Grant ANR-10-IAHU-01; Laboratoire d’Excellence Integrative Biology of Emerging Infectious Diseases Grant ANR-10-LABX-62-IBED; the Jefrey Modell Centers Network; the St. Giles Foundation; the Rockefeller University; INSERM; and Paris Descartes University. This study was supported in part by Japan Society for the Promotion of Science Grants in Aid for Scientific Research 16H05355 and 16K1552 and the Practical Research Project for RareInfectable Diseases of the Japan Agency for Medical Research and Development, AMED. R.L. was supported by the SNFMI (Bourse Marcel Simon), the INSERM PhD program for medical doctors (poste d’accueil INSERM), and a Fullbright grant (Franco-American commission). V.B. was supported by ANR Grant NKIR-ANR-13-PDOC-0025-01. K.M. was supported by a Japan Foundation for Pediatric Research fellowship grant. L.Y.A.C. was supported by the Singapore National Medical Research Council and National University Health System. F.G. is a scholar of the Else Kröner Fresenius Clinical Research School München “Rare diseases of the immune system—from pathophysiology to new therapies” (Grant 2013 Kolleg 18).


Lévy et al.